Liana Moussatos
Stock Analyst
(3.80)
# 4,648
Out of 4,648 analysts
69
Total ratings
61.9%
Success rate
41.38%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Liana Moussatos
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CLSD Clearside Biomedical | Maintains: Outperform | $5 → $4 | $1.03 | +288.35% | 4 | Mar 13, 2024 | |
| VRNA Verona Pharma | Reiterates: Outperform | $33 | $38.15 | -13.50% | 6 | Mar 1, 2024 | |
| UTHR United Therapeutics | Reiterates: Outperform | $308 | $376.80 | -18.26% | 10 | Feb 22, 2024 | |
| BPMC Blueprint Medicines | Reiterates: Outperform | $75 | $91.88 | -18.37% | 4 | May 23, 2023 | |
| LQDA Liquidia | Downgrades: Underperform | $4 → $3 | $10.46 | -71.32% | 5 | Sep 1, 2022 | |
| ASND Ascendis Pharma | Maintains: Outperform | $128 → $117 | $125.77 | -6.97% | 6 | Mar 3, 2022 | |
| PCRX Pacira BioSciences | Maintains: Outperform | $97 → $94 | $16.45 | +471.43% | 9 | Feb 28, 2022 | |
| XOMA XOMA Royalty | Downgrades: Neutral | $22 | $30.86 | -28.71% | 5 | Sep 7, 2021 | |
| AVTE Aerovate Therapeutics | Initiates: Outperform | $23 | $2.72 | +745.59% | 1 | Jul 26, 2021 | |
| LXRX Lexicon Pharmaceuticals | Downgrades: Neutral | $2 → $8 | $1.21 | +563.90% | 3 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $59 | $1.20 | +4,816.67% | 1 | Jun 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $175 → $164 | $66.01 | +148.45% | 6 | Mar 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $35 → $36 | $5.15 | +599.03% | 4 | Feb 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.49 | - | 5 | Jul 10, 2018 |
Clearside Biomedical
Mar 13, 2024
Maintains: Outperform
Price Target: $5 → $4
Current: $1.03
Upside: +288.35%
Verona Pharma
Mar 1, 2024
Reiterates: Outperform
Price Target: $33
Current: $38.15
Upside: -13.50%
United Therapeutics
Feb 22, 2024
Reiterates: Outperform
Price Target: $308
Current: $376.80
Upside: -18.26%
Blueprint Medicines
May 23, 2023
Reiterates: Outperform
Price Target: $75
Current: $91.88
Upside: -18.37%
Liquidia
Sep 1, 2022
Downgrades: Underperform
Price Target: $4 → $3
Current: $10.46
Upside: -71.32%
Ascendis Pharma
Mar 3, 2022
Maintains: Outperform
Price Target: $128 → $117
Current: $125.77
Upside: -6.97%
Pacira BioSciences
Feb 28, 2022
Maintains: Outperform
Price Target: $97 → $94
Current: $16.45
Upside: +471.43%
XOMA Royalty
Sep 7, 2021
Downgrades: Neutral
Price Target: $22
Current: $30.86
Upside: -28.71%
Aerovate Therapeutics
Jul 26, 2021
Initiates: Outperform
Price Target: $23
Current: $2.72
Upside: +745.59%
Lexicon Pharmaceuticals
Jan 29, 2021
Downgrades: Neutral
Price Target: $2 → $8
Current: $1.21
Upside: +563.90%
Jun 5, 2020
Initiates: Outperform
Price Target: $59
Current: $1.20
Upside: +4,816.67%
Mar 2, 2020
Maintains: Outperform
Price Target: $175 → $164
Current: $66.01
Upside: +148.45%
Feb 10, 2020
Maintains: Outperform
Price Target: $35 → $36
Current: $5.15
Upside: +599.03%
Jul 10, 2018
Downgrades: Neutral
Price Target: n/a
Current: $1.49
Upside: -